Hypersensitivity skin reactions in melanoma patients treated with vemurafenib after ipilimumab therapy.
James J. Harding
No relevant relationships to disclose
Mario E. Lacouture
Consultant or Advisory Role - Amgen; AVEO; Bayer; Bristol-Myers Squibb; GlaxoSmithKline; ImClone Systems; Onyx; OSI Pharmaceuticals; Pfizer; Roche/Genentech
Honoraria - Amgen; AVEO; Bayer; Bristol-Myers Squibb; GlaxoSmithKline; ImClone Systems; Onyx; OSI Pharmaceuticals; Pfizer; Roche/Genentech
Research Funding - GlaxoSmithKline
Melissa Pulitzer
No relevant relationships to disclose
Margaret Callahan
Research Funding - Bristol-Myers Squibb
Michael Andrew Postow
No relevant relationships to disclose
Richard D. Carvajal
Consultant or Advisory Role - Novartis
Research Funding - Bristol-Myers Squibb
Jedd D. Wolchok
Consultant or Advisory Role - Bristol-Myers Squibb
Honoraria - Bristol-Myers Squibb
Research Funding - Bristol-Myers Squibb
Paul B. Chapman
Consultant or Advisory Role - GlaxoSmithKline; Roche/Genentech
Research Funding - GlaxoSmithKline; Roche/Genentech